What Does Tirzepatide Actually Cost?

The question in one paragraph

Ask “how much is tirzepatide” and you’ll get a different answer depending on which of four separate pricing systems you land in: the manufacturer’s list price, a manufacturer self-pay program, an insurance-based copay, or a compounded version sold through a telehealth platform. These aren’t small variations.

The research shows list price for Zepbound sitting at $499 to $1,086.37 per fill and Mounjaro at $1,112.16 a month, while a manufacturer savings card can bring the same drug down to $25 a month for someone with qualifying commercial insurance, and Lilly’s own direct self-pay channel has priced doses anywhere from $299 to $699 depending on strength and the month you checked.

That’s four prices for one drug, and none of them is “the” price until you know which category a given reader falls into.

The decision this section exists to help with isn’t “is tirzepatide expensive” (list price answers that trivially) but “which of these paths actually applies to me, and what will I be billed after the discounts, memberships, and fine print are accounted for.” That’s genuinely non-obvious for a few reasons:

• There is no FDA-approved generic tirzepatide. When people search “tirzepatide generic price,” what they usually find instead is compounded tirzepatide from a 503A pharmacy, a different regulatory category entirely, priced in the research at roughly $100 to $300 a month rather than a true generic equivalent of the brand.
• The manufacturer savings card explicitly excludes Medicare, Medicaid, and TRICARE, so the widely advertised “$25/month” figure is not available to a large share of searchers regardless of insurance status.
• Self-pay pricing has been repriced multiple times by Lilly across 2025 and 2026, so a number that was accurate a few months ago may already be wrong.

Anyone comparing this to the cheapest GLP-1 without insurance or running the numbers on semaglutide cost without insurance is really asking the same underlying question from a different drug: does the list price, the self-pay price, or the compounded price apply to my situation, and which one is genuinely cheapest once monthly caps, dose escalation, and membership fees are factored in rather than just the advertised headline number.

The rest of this guide breaks those four pricing paths apart individually, with the caveat that self-pay and savings-card figures should be checked against Lilly’s current pricing page rather than treated as fixed.

For readers weighing tirzepatide against other approaches to weight management entirely, the Best Peptides for Weight Loss and Retatrutide pages cover adjacent options and their own cost and evidence considerations.

How it works

Every dollar figure attached to tirzepatide traces back to one of four distinct pathways, and which pathway a person lands on is what actually answers “how much is tirzepatide” for their situation.

The four pricing pathways

Brand list price (WAC). Eli Lilly publishes a wholesale acquisition cost for Zepbound ($499 to $1,086.37 per fill) and Mounjaro ($1,112.16/month). This is the number insurers negotiate against, not what most patients pay.

Insured price. Commercial plans that cover Zepbound or Mounjaro apply a copay, often stacked with Lilly’s manufacturer savings card, which can bring the cost as low as $25 for a 28-day (up to four-pen) supply.

Government-insured patients (Medicare, Medicaid, TRICARE) are excluded from this card by the program’s own terms, and Medicare Part D coverage differs by indication, generally treating Mounjaro’s diabetes use differently from Zepbound’s weight-loss use.

Brand self-pay (no insurance). Lilly’s direct-to-patient channel prices doses from roughly $299 up to $699 depending on strength, though these tiers have been repriced more than once since early 2025, so a current lookup at the point of purchase matters more than any published table.

If insurance exists but doesn’t cover the drug at all, the savings card can still cap cost near $499/month.

Compounded tirzepatide. Prepared by licensed 503A pharmacies and sold through telehealth platforms, this is not FDA-approved and is not a true “tirzepatide generic price” since no generic version of the drug currently exists, the term gets used loosely to describe compounded product.

Across several telehealth providers, compounded pricing clusters in the $130 to $300/month range depending on commitment length, with flat dosing tiers on some plans and dose-based price increases on others.

Where the pathways diverge

This same insured-versus-self-pay-versus-compounded structure is why “cheapest GLP-1 without insurance” searches often surface compounded telehealth offers alongside Lilly’s own self-pay tiers, and why semaglutide cost without insurance follows a similar three-lane pattern (list price, brand self-pay, compounded) even though semaglutide is a single-target GLP-1 agonist rather than tirzepatide’s dual GIP/GLP-1 mechanism.

Readers comparing across drug classes, including newer entrants like Retatrutide, will find the same pricing architecture applies regardless of which receptor the molecule targets.

What it costs

Numbers vary by path more than for almost any other drug cost question, so the table below separates list price from what people in the source set actually report paying.

There is no FDA-approved generic tirzepatide. When people search “tirzepatide generic price,” what they typically find is compounded tirzepatide from a 503A pharmacy, not a generic in the regulatory sense, a distinction Policy Lab, Fifty410, and Alloy all touch on when describing compounded tirzepatide as non-FDA-approved.

For anyone asking how much is tirzepatide without any coverage at all, the honest answer is a range, not a number: list price above $1,000, Lilly’s own direct self-pay program well under half that, and compounded versions lower still.

Government insurance is excluded from the $25 savings card entirely (Medicare, Medicaid, TRICARE), so those beneficiaries are pushed toward either full list price or the self-pay/compounded routes.

On the cheapest glp-1 without insurance question specifically, compounded tirzepatide from providers like BodyBuilding Health+, Raeliva, or Fifty410 clusters lower than any brand path, roughly $130 to $300/month depending on plan length and dose tier, per Policy Lab’s provider comparisons.

Semaglutide cost without insurance follows a similar shape: Fifty410 lists compounded semaglutide starting around $199/month, which sits above its own compounded tirzepatide tiers, one of the few direct semaglutide-vs-tirzepatide compounded price points in the source set.

A few pricing traps show up repeatedly across the compounded market: monthly rates that drop only if paid upfront for 3, 6, or 12 months, dose-escalation pricing where cost rises as mg strength increases, and “intro” prices that jump sharply at renewal, all documented by Policy Lab’s provider reviews.

Refund terms also differ sharply: Lilly’s direct-to-patient program is billed per shipment, while several compounded multi-month plans are non-refundable once medication ships.

Because Lilly has repriced its self-pay program at least twice in the period covered by this research, the self-pay figures above should be treated as a snapshot rather than fixed, and verified on Lilly’s current pricing page before assuming a specific number applies.

For a broader view of how tirzepatide fits among GLP-1 and related options, see Best Peptides for Weight Loss and Retatrutide.

The options compared

Every path to tirzepatide comes with a different trade-off between price, certainty, and regulatory footing. Four routes cover almost everyone asking “how much is tirzepatide”: brand product through commercial insurance, Lilly’s direct self-pay channel, the manufacturer savings card, and compounded tirzepatide from a 503A pharmacy.

Insured, brand product. This is the only route with FDA approval and a manufacturer safety monitoring program behind it, but coverage is inconsistent.

Forbes Health (weight 0.625) and Lilly’s own pricing page describe commercial plans covering Zepbound with prior authorization far more reliably than Medicare or Medicaid, which generally exclude weight-loss indications outright even when they cover Mounjaro for diabetes.

Lilly self-pay (LillyDirect). For the uninsured, this is Lilly’s own answer to “cheapest GLP-1 without insurance” among FDA-approved options, priced by dose rather than a flat rate.

It is genuine brand product with no prescription workaround, but pricing has been revised more than once (Pharmacy Times reported different figures in Feb 2025 than the site shows now), so the trade-off is administrative: no subscription lock-in, but numbers worth reverifying before assuming they’re current.

Manufacturer savings card. The route to the advertised $25/month, but it only functions as a discount on top of existing commercial coverage, not as a standalone low-cost path. Government beneficiaries are excluded by design, and if a plan doesn’t cover the drug at all, the card still leaves a self-pay floor around $499 (Forbes).

Compounded tirzepatide. There is no FDA-approved tirzepatide generic price to quote, since tirzepatide remains on-patent; compounded versions from 503A pharmacies are not generics in the regulatory sense, only lower-cost, non-FDA-approved preparations of the same active ingredient.

Policy Lab, Alloy, and Fifty410 converge on roughly $100 to $300/month, well under brand list price, but with real trade-offs: no FDA approval of the finished product, refund terms that end once a shipment goes out, and, per Policy Lab’s review methodology, pricing that can hide membership fees or dose-escalation charges behind a low headline number.

For comparison, semaglutide cost without insurance follows a similar pattern of high list price against much lower compounded pricing, per Fifty410’s compounded-semaglutide line starting around $199/month, which readers weighing tirzepatide against Best Peptides for Weight Loss alternatives may want as a reference point.

What to watch for

There is no FDA-approved generic tirzepatide. When people search “tirzepatide generic price,” what they usually find is compounded tirzepatide from a 503A pharmacy, priced in the roughly $100-$300/month range per multiple telehealth sources, not a true generic in the regulatory sense.

That distinction matters because the legal basis for mass compounding rested on an FDA-declared drug shortage; the FDA has since declared that shortage resolved, which changes the legal footing for 503A/503B compounding going forward.

None of the compounded-provider pages reviewed here address this shift in any depth, so a provider’s price today may not reflect its legal status tomorrow.

Pricing structures that change the real answer to “how much is tirzepatide”

A single number can’t answer “how much is tirzepatide” honestly, because at least one comparison source (Policy Lab) flags three patterns that shift the effective monthly cost after signup:

• Membership stacking – a low headline price plus a separate recurring platform or coaching fee (Alloy’s ~$100 starting price plus a $99/month membership fee is the clearest documented example).
• Dose-escalation pricing – cost rising as mg strength increases, true of Lilly Direct’s self-pay tiers ($299 up to $699 by dose) but not of most flat-rate compounded plans reviewed.
• Intro-vs-renewal pricing – a discounted starter price that jumps at renewal (Noom’s $149 intro versus $299/month ongoing).

Cancellation and refund terms also change the math: several compounded providers (Raeliva, Gala, BodyBuilding Health+ multi-month plans) do not refund once medication ships, while Lilly Direct is described as the only fully flexible, no-subscription option.

What shifts the number over time

Lilly’s own self-pay pricing has been repriced multiple times in roughly a year (Pharmacy Times’ Feb 2025 figures differ from the current Lilly pricing page), so any quoted figure should be treated as a snapshot, not a fixed price.

Savings-card terms are similarly fluid: Lilly states the program is subject to monthly and annual caps and can be changed or revoked at any time, with no public source quantifying exactly where those caps sit.

Cheapest-without-insurance framing

For readers comparing “cheapest glp-1 without insurance” options broadly, tirzepatide’s self-pay and compounded tiers sit in a similar range to reported “semaglutide cost without insurance” figures from the same telehealth providers (Fifty410 lists compounded semaglutide starting around $199/month), though no source in this research set did a rigorous head-to-head cost comparison of the two molecules.

Other flags worth checking before paying

• Whether a “cheap” compounded price includes syringes, shipping, or lab work, none of which is itemized consistently across providers reviewed.
• Whether the pharmacy is licensed 503A and discloses that the product is not FDA-approved, a disclosure Alloy and Fifty410 both include but that isn’t universal across the category.
• Whether insurance coverage, once approved, still requires prior authorization that can lapse or be denied on renewal.

Frequently asked questions